InteRNA Technologies
Prof. Bronkhorstlaan 10-92
Bilthoven
3723 MB
Tel: 31-30-229-6095
Website: http://www.interna-technologies.com/
30 articles about InteRNA Technologies
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors
12/2/2021
InteRNA Technologies announced it received Investigational New Drug clearance from the U.S. Food and Drug Administration for the company’s Phase I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors.
-
BioSpace Movers & Shakers, Oct. 22
10/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
10/19/2021
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the establishment of a Clinical Advisory Board and the appointment of new members to its Scientific Advisory Board.
-
InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
10/12/2021
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board.
-
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget
3/24/2021
Results further support the potential of lead candidate, INT-1B3, as novel option for therapeutic intervention in oncology
-
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
3/11/2021
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government.
-
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
-
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
2/16/2021
InteRNA Technologies announced that the first patient has been dosed in the first cohort of its first-in-human Phase I study with the Company’s lead microRNA candidate, INT-1B3.
-
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
2/9/2021
Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic
-
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
5/6/2020
First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3
-
BioSpace Global Roundup, May 16
5/16/2019
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more. -
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
5/15/2019
InteRNA Technologies announced today the recent publication of data from a collaboration with University Medical Center (UMC) Utrecht in Journal of Neuroscience showing that the downregulation of miR-135a levels can reduce seizure activity after the onset of spontaneous recurrent seizures (SRS) in chronic-stage Mesial Temporal Lobe Epilepsy (mTLE) in mouse models
-
BioSpace Movers and Shakers: March 29
3/29/2019
Biotech and pharma companies bring on new talent to strengthen leadership teams and boards. -
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
3/25/2019
InteRNA Technologies announced today the appointment of Andrea van Elsas, Ph.D., as a new member of the Company’s Scientific Advisory Board (SAB).
-
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
10/1/2018
Two poster presentations highlight INT-1B3’s immune-system activation and CD8+ T cell-driven anti-tumor response in addition to its distinct MoA, targeting multiple hallmarks of cancer.
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
4/18/2018
INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pronounced long term immunity
-
InteRNA Technologies Secures Final Extension Series A Financing And Strengthens Its Supervisory Board
10/29/2015
-
InteRNA Technologies, UCB, Inc. And University of Bonn To Collaborate On The Role Of MicroRNAs In Neurodegenerative Disease
1/10/2014